Skip to main content

Table 2 ERBB2 and ERBB3 mutations in different stages of lobular neoplastic progression

From: Invasive lobular carcinoma of the breast: the increasing importance of this special subtype

Study ERBB2 alteration frequency ERBB3 alteration frequency Notes
Total % Mut Amp Total % Mut Amp
In situ Harrison et al. [27] 94.7% 13/19 6/19 21% 4/19 0/19 17 PLCIS; 2 FLCIS
Shamir et al. [33] 50% 6/16 2/16 18.7% 3/16 0/16 10 PLCIS; 6 FLCIS; ERBB2 and/or ERBB3 alterations in 60% PLCIS and 50% FLCIS
Primary ILC Zhu et al. [37] 17.6% 3/17 23.5% 4/17 PILC
Rosa-Rosa et al. [36] 26% 7/27 1/27 PILC; association with nuclear grade 3
Christgen et al. [41] 5% 5/106 Grade 3 but no association with solid or pleomorphic
Cao et al. [42] 19% 13/70 Amplification; no mutation assessment
Deniziaut et al. [43] 15% 6/55 0% 0/55 Grade 3; positive association with solid presentation
Ping et al. [44] 6% 6/100 CDH1 altered with ERBB2 mutation correlates with poor prognosis
Lien et al. [31] 52.2% 5/24 8/24 PILC; 2% in classic ILC
mILC Ma et al. [45] 7.8% 4/51 Metastatic ILC; confirmed neratinib efficacy in ERBB2 mutants in phase II trial; detection in ctDNA
Ross et al. [46] 22.7% 4/22 1/22     Relapsed ILC; ERBB2 mutation enriched in CDH1 mutant tumours; I gene fusion not tabulated (ERBB2GRB7)
  1. CILC classic ILC, ctDNA circulating tumour DNA, FLCIS florid LCIS, mILC metastatic ILC, PILC pleomorphic ILC, PLCIS pleomorphic LCIS